US 12,377,191 B2
Chondroinductive peptides and compositions and methods of use thereof
Michael S. Detamore, Norman, OK (US); and Salma Mahzoon, Eldridge, MD (US)
Assigned to The Board of Regents of the University of Oklahoma, Norman, OK (US)
Appl. No. 17/271,339
Filed by The Board of Regents of the University of Oklahoma, Norman, OK (US)
PCT Filed Aug. 28, 2019, PCT No. PCT/US2019/048604
§ 371(c)(1), (2) Date Feb. 25, 2021,
PCT Pub. No. WO2020/047123, PCT Pub. Date Mar. 5, 2020.
Claims priority of provisional application 62/723,674, filed on Aug. 28, 2018.
Prior Publication US 2021/0346573 A1, Nov. 11, 2021
Int. Cl. A61L 27/26 (2006.01); A61K 38/08 (2019.01); A61K 47/61 (2017.01); A61K 47/65 (2017.01); A61L 27/22 (2006.01); A61L 27/52 (2006.01); C07K 14/00 (2006.01)
CPC A61L 27/26 (2013.01) [A61K 38/08 (2013.01); A61K 47/61 (2017.08); A61K 47/65 (2017.08); A61L 27/227 (2013.01); A61L 27/52 (2013.01); C07K 14/00 (2013.01); A61L 2300/25 (2013.01); A61L 2300/412 (2013.01); A61L 2300/622 (2013.01); A61L 2430/06 (2013.01)] 16 Claims
 
1. A chondroinductive composition, comprising: (a) a polymer scaffold, (b) a cell adhesion peptide linked to the polymer scaffold, and (c) a chondroinductive peptide linked to the polymer scaffold, wherein the chondroinductive peptide consists of a linker and an amino acid sequence X1-X2-X3-X4-X5-X6 (SEQ ID NO: 1), wherein the linker extends from the polymer scaffold to the N-terminal end of X1 and consists of 1 to 44 amino acids, and wherein X1 and X6 are independently selected from threonine and serine; X2, X3 and X5 are independently selected from proline, 3-hydroxyproline, and 4-hydroxyproline; and X4 is glutamic acid or aspartic acid.